What is it and how is it used?
Kentera is used in adults to control the symptoms of urge incontinence and/or increased urinary frequency and urgency.
Kentera works by allowing the bladder to expand and accommodate more urine.
Ad
Substance(s) | Oxybutynin |
Admission country | United Kingdom |
Manufacturer | Nicobrand Ltd. |
Narcotic | No |
ATC Code | G04BD04 |
Pharmacological group | Urologicals |
Kentera is used in adults to control the symptoms of urge incontinence and/or increased urinary frequency and urgency.
Kentera works by allowing the bladder to expand and accommodate more urine.
Ad
If you have any of the following:
Since treatment with oxybutynin may cause decreased perspiration, there is an increased risk of fever and heat stroke if you are exposed to high environmental temperatures.
Kentera is not recommended for use in children or adolescents.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Applying the Kentera patch at the same time as taking other medicines that have similar side effects such as dry mouth, constipation and drowsiness, may increase how often and how severe these side effects are experienced.
Oxybutynin may slow the digestive tract and thereby influence the adsorption of other oral medicines, or the use of this medicine together with other medicines may increase the effect of oxybutynin. Especially:
Oxybutynin may cause drowsiness or blurred vision. Drowsiness may be increased by consumption of alcohol.
Ask your doctor for advice before taking any medicine.
Kentera should not be used during pregnancy unless clearly necessary.
When oxybutynin is used during breast-feeding, a small amount is excreted in the mother?s milk. Use of oxybutynin while breast-feeding is therefore not recommended.
Because Kentera may produce drowsiness, somnolence, or blurred vision, patients should be advised to exercise caution when driving or using machinery.
Ad
Always use Kentera exactly as your doctor has instructed you. You should check with your doctor or pharmacist if you are not sure.
Apply a new Kentera patch twice weekly (every 3 to 4 days) according to the instructions for use. Change the patch on the same two days every week, for example, every Sunday and Wednesday or Monday and Thursday. Printed on the inside flap of your Kentera package, you will find a Kentera calendar checklist that will help you to remember your dosing schedule. Mark the schedule you plan to follow and remember always to change your patch on the same two days of the week you have chosen on your calendar. Make sure to wear only one patch at a time and wear your patch continuously, until it is time to apply a new one.
Where to apply
Apply the patch to a clean, dry, smooth area of skin on your abdomen, hips or buttocks. Avoid placing the patch in the waistline area to prevent tight clothing from rubbing against the patch. Do not expose the patch to the sun. Place the patch underneath your clothing. Rotate application sites with each new application. Do not apply a patch to the same place on your body for at least 1 week.
How to apply
Each patch is individually sealed in a protective sachet. Please read all the information below before you begin to apply Kentera .
Bathing, showering, swimming andexercise:
You should wear each patch all the time until you apply a new one. Baths, showers, swimming and exercise should not affect the patch as long as you don?t rub the patch as you wash. Avoid soaking in a hot bath for a long period of time, which can make the patch come off.
If the patch starts to lift off your skin, apply a little bit of pressure using your fingertips. The patch is designed to re-stick. Very rarely will the patch come off completely. If it does, try putting the same patch back on the same spot. If it sticks firmly all over, leave it on. If not, take it off and put a new patch on a new spot. No matter what day this happens, continue with the twice-a-week schedule that you have marked on your patch box.
As soon as you remember, remove the old patch and apply a new one to a new spot on your abdomen, hips or buttocks. No matter what day this happens, continue with the same twice-a-week schedule for your next patch, even if it means changing the new patch before 3 to 4 days have elapsed.
How to remove
When changing the patch, remove the old patch slowly. Fold it in half (sticky sides together) and throw it away to keep out of the reach of children and pets. Mild redness may be present at the application site. This redness should disappear within several hours after removal of the patch. If irritation persists, please contact your doctor.
Gently washing the application site with warm water and a mild soap should remove any adhesive that remains on your skin after removal of the patch. A small amount of baby oil may also be used to remove any excess residue. Rings of adhesive that become soiled may require a medical adhesive removal pad that should be available from your pharmacist. Alcohol or other strong solvents may cause skin irritation and should not be used.
After use the patch still contains substantial quantities of active ingredients. Remaining active ingredients of the patch may have harmful effects if reaching the aquatic environment. Hence, after removal, the used patch should be folded in half, adhesive side inwards so that the release membrane is not exposed, placed in the original sachet and then discarded safely out of reach of children. Any used or unused patches should be discarded according to local requirements or returned to the pharmacy. Used patches should not be flushed down the toilet nor placed in liquid waste disposal systems.
The patient should not apply more than one patch at a time.
Apply a Kentera patch as soon as you realise your patch is missing, or you have missed a scheduled day of application.
Your urge incontinence may return and you may have increased urinary frequency if you decide to stop using the patch. Continue to use Kentera as long as your doctor tells you to.
Talk to your doctor or pharmacist if you have any questions on the use of this medical product.
Ad
Like all medicines, Kentera can cause side effects, although not everybody gets them.
The frequency of possible side effects listed below is defined using the following convention:
Very common side effect:
Common side effects:
Uncommon side effects:
If any of the side effects get serious, or if you notice any side effects not listed in the leaflet, please tell your doctor.
Ad
Keep out of the reach and sight of children.
Do not use Kentera after the date shown on the sachet and the carton.
Do not refrigerate or freeze.
The used patches should be folded in half, adhesive side inwards so that the release membrane is not exposed, placed in the original sachet and then discarded safely out of the reach of children. Any used or unused patches should be discarded according to local requirements or returned to the pharmacy. Used patches should not be flushed down the toilet nor placed in liquid waste disposal systems.
Ad
The active substance is oxybutynin. Each transdermal patch releases 3.9 mg of oxybutynin per 24 hours. Each patch of 39 cm 2 contains 36 mg of oxybutynin.
The other ingredients are: Each patch contains triacetin, and acrylic adhesive solution. The oxybutynin, triacetin and acrylic adhesive are coated on clear PET/EVA backing film and covered with a siliconised polyester release liner.
Kentera is a transdermal patch and it is packaged in cartons containing 2, 8, and 24 patches. Each patch consists of a clear backing film that has the pharmaceutical ingredients coated on the side containing the protective backing film. The backing film is to be removed prior to patch application.
Nicobrand Limited
189 Castleroe Road
Coleraine
Northern Ireland
BT51 3RP
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
BelgiëBelgiqueBelgien Eurocept BV TélTel 31 0 35 528 8377 LuxembourgLuxemburg Eurocept BV TélTel 31 0 35 528 8377
Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc. Te. 44 0 28 7086 8733 Magyarország Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc. Nagy-Britannia Tel. 44 0 28 7086 8733 eská republika Herbacos Recordati s.r.o. Tel 420 466 741 915 Malta Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc. Ir-Renju Unit Tel 44 0 28 7086 8733 Danmark Orion Pharma AS Tlf 45 49 12 66 00 Nederland Eurocept BV Tel 31 0 35 528 8377 Deutschland Merckle Recordati GmbH Tel 49 0 731 7047 0 Norge Orion Pharma AS Tlf 47 40 00 42 10 Österreich Merckle Recordati GmbH Deutschland Tel 49 0 731 7047 0 Eesti Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc. Ühendkuningriik Tel 44 0 28 7086 8733 Recordati Hellas Pharmaceuticals A.E. 30 210-6773822 Polska Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc. Wielka Brytania Tel. 44 0 28 7086 8733 España Recordati España, S.L. Tel 34 91 6591550 Portugal Jaba Recordati S.A. Tel 351 21 4329 500 France Bouchara Recordati Laboratories Tél 33 0 1 45 19 10 00 România Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc. Marea Britanie Tel 44 0 28 7086 8733 Ireland Recordati Ireland Ltd. Tel 44 0 845 0942936 Slovenija Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc. Velika Britanija Tel 44 0 28 7086 8733 Slovenská republika Herbacos Recordati s.r.o. eská republika Tel 420 466 741 915 Ísland Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc. Bretland Sími 44 0 28 7086 8733 Italia Innova Pharma S.p.A. Tel 39 02 48787.1 SuomiFinland Orion Corporation PuhTel 358 10 4261
Sverige Orion Pharma AB Tel 46 8 623 64 40 Recordati Hellas Pharmaceuticals A.E. 30 210-6773822 United Kingdom Orion Pharma UK Ltd Tel 44 0 1635 520300 Latvija Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc. Lielbritnija Tel 44 0 28 7086 8733 Lietuva Nicobrand Limited A Subsidiary of Watson Pharmaceuticals, Inc. Jungtin Karalyst Tel 44 0 28 7086 8733
Ad
Substance(s) | Oxybutynin |
Admission country | United Kingdom |
Manufacturer | Nicobrand Ltd. |
Narcotic | No |
ATC Code | G04BD04 |
Pharmacological group | Urologicals |
Ad